Enanta Pharmaceuticals (ENTA) Expected to Announce Quarterly Earnings on Wednesday

Enanta Pharmaceuticals (NASDAQ:ENTA) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of ($1.16) per share and revenue of $17.25 million for the quarter.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The firm had revenue of $14.60 million during the quarter, compared to analyst estimates of $17.99 million. During the same period in the previous year, the firm posted ($1.33) earnings per share. The company’s quarterly revenue was down 22.8% compared to the same quarter last year. On average, analysts expect Enanta Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Enanta Pharmaceuticals Trading Down 3.4 %

Shares of NASDAQ ENTA opened at $5.12 on Wednesday. Enanta Pharmaceuticals has a twelve month low of $4.71 and a twelve month high of $17.80. The stock has a fifty day simple moving average of $6.65 and a 200-day simple moving average of $10.33. The stock has a market capitalization of $108.49 million, a PE ratio of -0.93 and a beta of 0.56.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ENTA. Robert W. Baird dropped their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. JMP Securities reissued a “market outperform” rating and set a $21.00 target price (down from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. Finally, HC Wainwright decreased their price target on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, December 24th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.25.

Insider Activity

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the completion of the sale, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at $6,461,202.28. This represents a 0.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 13.64% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.